Imagine going to the doctor’s office when you’re sick and getting diagnosed with a rare condition. You might feel scared about what comes next, you might be worried about how your life will be impacted, you could even feel relief for finally having a diagnosis. Now imagine the prescription to...
Latest News
CHARLOTTE, N.C. — Adaptin Bio, Inc. (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted delivery to the brain and other difficult-to-reach tissues, today announced that the Preston Robert Tisch Brain Tumor Center has granted the first Institutional Review Board (IRB) approval for the Company’s...
SAN DIEGO, Calif. — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE). Additionally, ADARx announced that the U.S. Food and Drug Administration...
SAN DIEGO, Calif. — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced Phase 1/2 clinical data for onvuzosiran (ADX-324), an investigational small interfering RNA (siRNA) therapeutic candidate being developed for the treatment of hereditary angioedema (HAE). The Company also highlighted the clinical trial design...
SAN DIEGO – ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, today announced the completion of a $75 million Series B financing to advance its drug development pipeline. The Series B was co-led by SR One Capital Management and OrbiMed Advisors. Sirona Capital joined this financing as well...
LAUSANNE, Switzerland – ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma...
LAUSANNE, Switzerland — ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted...
LAUSANNE, Switzerland – ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer, will...
LAUSANNE, Switzerland — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with...
LAUSANNE, Switzerland – ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™ (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines) in oncology...